These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16318951)

  • 41. Tetracycline derivatives reduce binge alcohol consumption in High Drinking in the Dark mice.
    Crabbe JC; Ozburn AR; Hitzemann RJ; Spence SE; Hack WR; Schlumbohm JP; Metten P
    Brain Behav Immun Health; 2020 Apr; 4():100061. PubMed ID: 34589846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice.
    Huynh N; Arabian NM; Asatryan L; Davies DL
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30663649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of mifepristone effects on alcohol-seeking and self-administration in baboons.
    Holtyn AF; Weerts EM
    Exp Clin Psychopharmacol; 2019 Jun; 27(3):227-235. PubMed ID: 30570274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overcoming the "Valley of Death" in Medications Development for Alcohol Use Disorder.
    Ray LA; Bujarski S; Roche DJO; Magill M
    Alcohol Clin Exp Res; 2018 Sep; 42(9):1612-1622. PubMed ID: 29969156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?
    Pomrenze MB; Fetterly TL; Winder DG; Messing RO
    Alcohol Clin Exp Res; 2017 Dec; 41(12):1986-1999. PubMed ID: 28940382
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.
    Crabbe JC; Ozburn AR; Metten P; Barkley-Levenson A; Schlumbohm JP; Spence SE; Hack WR; Huang LC
    Pharmacol Biochem Behav; 2017 Sep; 160():55-62. PubMed ID: 28827047
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Baclofen and naltrexone effects on alcohol self-administration: Comparison of treatment initiated during abstinence or ongoing alcohol access in baboons.
    Holtyn AF; Kaminski BJ; Weerts EM
    Drug Alcohol Depend; 2017 Oct; 179():47-54. PubMed ID: 28753481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Further characterization of the GlyT-1 inhibitor Org25935: anti-alcohol, neurobehavioral, and gene expression effects.
    Lidö HH; Jonsson S; Hyytiä P; Ericson M; Söderpalm B
    J Neural Transm (Vienna); 2017 May; 124(5):607-619. PubMed ID: 28161754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development.
    Litten RZ; Falk DE; Ryan ML; Fertig JB
    Alcohol Clin Exp Res; 2016 Jul; 40(7):1368-79. PubMed ID: 27184259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preclinical Medication Development: New Targets and New Drugs.
    Kasten CR; Boehm SL
    Alcohol Clin Exp Res; 2016 Jul; 40(7):1418-24. PubMed ID: 27177689
    [No Abstract]   [Full Text] [Related]  

  • 51. Binge alcohol drinking elicits persistent negative affect in mice.
    Lee KM; Coehlo M; McGregor HA; Waltermire RS; Szumlinski KK
    Behav Brain Res; 2015 Sep; 291():385-398. PubMed ID: 26048424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The importance of animals in advancing research on alcohol use disorders.
    Helms CM; Bell RL; Bennett AJ; Davies DL; Chester JA; Kosten TA; Leeman RF; Panicker S; Platt DM; Weiner JL; Edwards S
    Alcohol Clin Exp Res; 2015 Apr; 39(4):575-8. PubMed ID: 25833015
    [No Abstract]   [Full Text] [Related]  

  • 53. Preclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation.
    Phillips TJ; Reed C; Pastor R
    Genes Brain Behav; 2015 Jan; 14(1):98-135. PubMed ID: 25565358
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rodent models of genetic contributions to motivation to abuse alcohol.
    Crabbe JC
    Nebr Symp Motiv; 2014; 61():5-29. PubMed ID: 25306777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Making organisms model human behavior: situated models in North-American alcohol research, since 1950.
    Ankeny RA; Leonelli S; Nelson NC; Ramsden E
    Sci Context; 2014 Sep; 27(3):485-509. PubMed ID: 25233743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence.
    Bell RL; Lopez MF; Cui C; Egli M; Johnson KW; Franklin KM; Becker HC
    Addict Biol; 2015 Jan; 20(1):38-42. PubMed ID: 24215262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of varenicline on alcohol seeking and self-administration in baboons.
    Kaminski BJ; Weerts EM
    Alcohol Clin Exp Res; 2014 Feb; 38(2):376-83. PubMed ID: 24033702
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
    Krishnan-Sarin S; O'Malley S; Krystal JH
    Alcohol Res Health; 2008; 31(4):400-7. PubMed ID: 23584013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetic research: who is at risk for alcoholism.
    Foroud T; Edenberg HJ; Crabbe JC
    Alcohol Res Health; 2010; 33(1-2):64-75. PubMed ID: 23579937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of naltrexone on post-abstinence alcohol drinking in C57BL/6NCRL and DBA/2J mice.
    Tomie A; Azogu I; Yu L
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():240-7. PubMed ID: 23499782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.